provides general information regarding cytisine

Quit Smoking with Tabex
Sopharma Shop

Achieve Life Sciences, Inc. (NASDAQ:ACHVGet Rating) – Equities researchers at Zacks Small Cap issued their FY2025 earnings estimates for shares of Achieve Life Sciences in a research report issued on Wednesday, May 10th. Zacks Small Cap analyst J. Vandermosten forecasts that the biopharmaceutical company will earn $2.16 per share for the year. The consensus estimate for Achieve Life Sciences’ current full-year earnings is ($1.94) per share.

A number of other equities research analysts have also recently commented on ACHV. Maxim Group raised their price target on shares of Achieve Life Sciences from $8.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday. Oppenheimer reaffirmed an “outperform” rating and issued a $17.00 price objective on shares of Achieve Life Sciences in a research note on Friday, March 17th.

Achieve Life Sciences Stock Down 3.0 %

NASDAQ:ACHV traded down $0.27 during trading hours on Friday, reaching $8.61. The company had a trading volume of 27,317 shares, compared to its average volume of 128,153. The company has a quick ratio of 1.27, a current ratio of 1.27 and a debt-to-equity ratio of 0.01. The firm has a market cap of $154.38 million, a price-to-earnings ratio of -2.19 and a beta of 1.52. The business’s 50-day simple moving average is $6.64 and its two-hundred day simple moving average is $4.56. Achieve Life Sciences has a twelve month low of $2.00 and a twelve month high of $10.30.

Achieve Life Sciences (NASDAQ:ACHVGet Rating) last issued its quarterly earnings data on Thursday, March 16th. The biopharmaceutical company reported ($0.83) EPS for the quarter, beating the consensus estimate of ($0.90) by $0.07. During the same quarter in the prior year, the company posted ($0.76) earnings per share.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the company. Tower Research Capital LLC TRC raised its position in Achieve Life Sciences by 75.6% in the first quarter. Tower Research Capital LLC TRC now owns 3,646 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 1,570 shares during the period. Prelude Capital Management LLC purchased a new position in shares of Achieve Life Sciences in the second quarter worth about $49,000. Charles Schwab Investment Management Inc. purchased a new position in shares of Achieve Life Sciences in the first quarter worth about $79,000. Bank of New York Mellon Corp purchased a new position in shares of Achieve Life Sciences in the first quarter worth about $79,000. Finally, Beaumont Financial Advisors LLC purchased a new position in shares of Achieve Life Sciences in the first quarter worth about $82,000. 21.11% of the stock is owned by institutional investors.

About Achieve Life Sciences

(Get Rating)

Achieve Life Sciences, Inc is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Its products includes cytisine, a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to

Before you consider Achieve Life Sciences, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Achieve Life Sciences wasn’t on the list.

While Achieve Life Sciences currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Elon Musk’s Next Move

Wondering when you’ll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Elon Musk's Next Move Cover